CN101808647A - 通过抑制Gpr12治疗认知障碍的方法 - Google Patents

通过抑制Gpr12治疗认知障碍的方法 Download PDF

Info

Publication number
CN101808647A
CN101808647A CN200880023965A CN200880023965A CN101808647A CN 101808647 A CN101808647 A CN 101808647A CN 200880023965 A CN200880023965 A CN 200880023965A CN 200880023965 A CN200880023965 A CN 200880023965A CN 101808647 A CN101808647 A CN 101808647A
Authority
CN
China
Prior art keywords
gpr12
training
mammal
memory
sirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880023965A
Other languages
English (en)
Chinese (zh)
Inventor
M·彼得斯
R·E.·M.·斯科特
T·P.·塔利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helicon Therapeutics Inc
Original Assignee
Helicon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helicon Therapeutics Inc filed Critical Helicon Therapeutics Inc
Publication of CN101808647A publication Critical patent/CN101808647A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN200880023965A 2007-05-15 2008-05-15 通过抑制Gpr12治疗认知障碍的方法 Pending CN101808647A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93816307P 2007-05-15 2007-05-15
US60/938,163 2007-05-15
PCT/US2008/063804 WO2008144453A1 (en) 2007-05-15 2008-05-15 Methods of treating cognitive disorders by inhibition of gpr12

Publications (1)

Publication Number Publication Date
CN101808647A true CN101808647A (zh) 2010-08-18

Family

ID=40122145

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880023965A Pending CN101808647A (zh) 2007-05-15 2008-05-15 通过抑制Gpr12治疗认知障碍的方法

Country Status (11)

Country Link
US (2) US7968524B2 (https=)
EP (1) EP2162137B1 (https=)
JP (1) JP2010527375A (https=)
KR (1) KR20100029079A (https=)
CN (1) CN101808647A (https=)
AU (1) AU2008254905A1 (https=)
BR (1) BRPI0811625A2 (https=)
CA (1) CA2684920A1 (https=)
IL (1) IL202091A0 (https=)
MX (1) MX2009012316A (https=)
WO (1) WO2008144453A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2545795T3 (es) 2009-04-09 2015-09-15 Cognition Therapeutics, Inc. Inhibidores del deterioro cognitivo
CN102595884B (zh) 2009-07-31 2014-12-03 考格尼申治疗股份有限公司 认知衰退的抑制剂
WO2011106785A2 (en) * 2010-02-26 2011-09-01 Cognition Therapeutics, Inc. Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
BR112013019775A2 (pt) 2011-02-02 2017-04-18 Cognition Therapeutics Inc composto, composição farmacêutica e método para tratar declínio cognitivo ou doença de alzheimer em um paciente
RU2692258C2 (ru) 2014-01-31 2019-06-24 Когнишн Терапьютикс, Инк. Композиции изоиндолина и способы лечения нейродегенеративного заболевания
DK3634394T3 (da) 2017-05-15 2026-03-02 Cognition Therapeutics Inc Sammensætninger til behandling af neurogenerative sygdomme
BR102022009685A2 (pt) * 2022-05-18 2023-11-28 Fundação Oswaldo Cruz Método para triagem de fármacos ou substâncias com potencial neuroprotetor, kit para triagem de fármacos ou substâncias, e, uso de um painel de genes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100283601B1 (ko) * 1993-02-19 2001-03-02 아만 히데아키 글리세롤 유도체, 디바이스 및 의약 조성물
US5858988A (en) * 1993-02-24 1999-01-12 Wang; Jui H. Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
US6291438B1 (en) * 1993-02-24 2001-09-18 Jui H. Wang Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
ATE386131T1 (de) * 1994-04-13 2008-03-15 Univ Rockefeller Aav-vermittelte überbringung von dna in zellen des nervensystems
US5684143A (en) * 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US6653086B1 (en) * 1998-04-14 2003-11-25 Arena Pharmaceuticals, Inc. Endogenous constitutively activated G protein-coupled orphan receptors
WO2001048483A2 (en) * 1999-12-10 2001-07-05 Astrazeneca Ab Method for screening of appetite control agents
US20040224316A1 (en) * 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
US20060247194A1 (en) * 2000-08-30 2006-11-02 Sirna Therapeutics , Inc. Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
CA2429814C (en) * 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
US6586524B2 (en) * 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
US20040023384A1 (en) * 2002-07-31 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of G protein-coupled receptor 12 expression
US20050106731A1 (en) 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
AU2003261449A1 (en) * 2002-08-07 2004-02-25 Compositions for rna interference and methods of use thereof
WO2004038407A2 (en) * 2002-10-24 2004-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
US7829694B2 (en) * 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US20070104688A1 (en) * 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
KR20060036466A (ko) * 2003-09-19 2006-04-28 패러다임 테라퓨틱스 리미티드 수용체
EP2270513A3 (en) * 2004-04-20 2011-04-06 Galapagos N.V. Methods, compositions and compound assays for inhibiting amyloid-beta protein production

Also Published As

Publication number Publication date
CA2684920A1 (en) 2008-11-27
MX2009012316A (es) 2009-12-03
EP2162137A1 (en) 2010-03-17
US20090022667A1 (en) 2009-01-22
KR20100029079A (ko) 2010-03-15
US20110281936A1 (en) 2011-11-17
WO2008144453A9 (en) 2010-03-18
WO2008144453A1 (en) 2008-11-27
US7968524B2 (en) 2011-06-28
AU2008254905A1 (en) 2008-11-27
EP2162137A4 (en) 2011-06-08
JP2010527375A (ja) 2010-08-12
BRPI0811625A2 (pt) 2014-11-11
EP2162137B1 (en) 2016-11-23
IL202091A0 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
TWI543763B (zh) Ｈｓｐ４７表現之調節
CN102014928A (zh) 使用小干扰RNA(siRNA)鉴别参与记忆形成的基因的方法
US20100113332A1 (en) Method of treating an inflammatory disease by double stranded ribonucleic acid
HK1210216A1 (en) Double-stranded oligonucleotide molecules to p53 and methods of use thereof
CN101557831A (zh) 体内抑制在灵长类亨廷顿基因表达的方法和序列
CN102666856A (zh) 用于向脊髓递送siRNA的方法和由此产生的疗法
EP2162137B1 (en) Methods of treating cognitive disorders by inhibition of gpr12
JP2009533475A (ja) 脾臓チロシンキナーゼ関連する炎症状態のｒｎａｉを介した阻害
CN118638786B (zh) 靶向acsl4基因的反义寡核苷酸及其应用
US9926565B2 (en) Aptamer-RNAi therapeutic compositions
CN118202055A (zh) 一种抑制SCN9A基因表达的siRNA、其药物组合物及用途
AU2024352343A1 (en) Antisense oligonucleotides for the treatment of canavan disease
EP4720283A1 (en) Oligonucleotides targeting gal3st1

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100818